DMPI
Pues a ver qué pasa las próximas 7 sesiones hasta la fecha del AACR...
Si los resultados de esas 2 fases II son buenas, perfecto, pero como sean malas...
Por otra parte, parece que el compuesto REM-001 de la empresa adquirida, es prometedor...
1. In four Phase 2 and/or Phase 3 clinical trials in CMBC , primarily targeting patients who had previously failed radiation therapy, our REM-001 Therapy was able to reduce or eliminate a substantial number of the treated CMBC tumors.
Specifically, our analysis of the data collected from these trials (shown in the chart below) indicates that in approximately 80% of evaluable tumor sites treated with REM-001 Therapy, there was a complete response; meaning that follow-up clinical assessments indicated no visible evidence of the tumor remaining.
2. REM-001 Therapy has also been studied in patients with basal cell nevus syndrome ("BCCNS") who developed extensive basal cell carcinoma. BCCNS is a rare but serious condition that is often characterized by the formation of multiple and recurring cutaneous basal cell carcinoma lesions. The FDA granted orphan-drug designation to REM-001 in the rare disease indication of BCCNS in January 2018. In a Phase 1/2 clinical trial (CA001B), 14 patients with BCCNS were enrolled and treated with REM-001 Therapy. A total of 157 lesions were treated in these patients and showed a 91% overall response rate. This was composed of a 68% complete lesion response rate (no remaining visible evidence of a lesion) and a 23% partial lesion response rate (lesion was reduced in size by more than 50%). In addition, 7% of lesions had stable disease (any increase in lesion size was less than 25%). The various response rates are shown in the graph below and are similar to the results seen in CMBC patients as we would expect.